Balanced Portfolio - Add 2% Telix Phama(TLX)
Date: 19/12/2023
*** GENERAL AVICE ONLY***
Telix Pharmaceuticals (TLX) presents an exciting opportunity in our balanced portfolio, showcasing significant advancements in the biotech and cancer treatment sector. As a pioneering company, Telix is rolling out its first approved product, Illuccix, for prostate cancer imaging, while actively developing a robust pipeline of assets for both imaging and therapy. This includes the promising TLX250CDx for kidney cancer imaging and the advanced therapeutic asset TLX591. With Illuccix already approved in key markets like the USA, Australia, and Canada, and pending submissions in Europe and Asia, Telix is rapidly expanding its global footprint. The company’s innovative use of radioactive isotopes positions it at the forefront of a revolutionary approach in cancer care, promising to dramatically improve patient outcomes and reshape clinical practices. The potential market size for Telix’s products, particularly in the US, underscores significant financial growth opportunities.
Telix Pharma (TLX) – Total Portfolio Allocation 4%
Entry: $9.50 | Target: $13 | Stop: $7.5
Disclaimer: The recommendation given is general advice only. It does not take into account your personal objectives, financial situation, or specific needs. This information should not be your sole resource when making such decisions. We strongly recommend you to seek the advice of financial, taxation, and legal professionals before finalising any investment decisions.